BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CT-P44 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CT-P44\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06952478-3384@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:CT-P44: Phase 3 readout est. (NCT06952478)
DESCRIPTION:CT-P44\, phase 3\, Multiple Myeloma.\nStudy: A Study to Compare
  Pharmacokinetics\, Efficacy and Safety of Subcutaneous CT-P44 and Darzale
 x Faspro in Combination With Lenalidomide and Dexamethasone in Patients Wi
 th Refractory or Relapsed Multiple Myeloma\nEstimated primary completion: 
 8 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ct-p44#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0695
 2478
URL:https://assetmemo.bio/drug/ct-p44#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
